Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2020

View Archived Issues

Boehringer Ingelheim begins home-based phase II study of BI-1358894 for MDD

Shock and kill with less toxicity

MANIFEST study results of CPI-0610 in advanced myelofibrosis set up phase III study

Programmed necrosis has role in post-flu bacterial infections

Meissa completes pre-IND meeting for COVID-19 vaccine candidate MV-014-210

Phase III study of pracinostat plus azacytidine in AML discontinued due to lack of efficacy

LAMC2 identified as a therapeutic target in PDAC

Yuhan discovers semicarbazide-sensitive amine oxidase inhibitors

CREDO 2 pivotal global phase III study of olokizumab meets endpoints

New E-NPP 2 inhibitors identified at Roche

Janssen synthesizes new cyclopentyl nucleoside analogues

Spanish approval granted for COVID-19 study using EnteraGam

Heptares Therapeutics identifies new orexin OX1 receptor antagonists

Lilly patents TYK2 JH2 domain ligands

Phase III trial of Kevzara in COVID-19 does not meet primary and key secondary endpoints

FDA approves Rukobia for the treatment of adults with multidrug-resistant HIV-1 infection

First patient dosed in phase II study of ICP-192 for cholangiocarcinoma

FDA approves Byfavo injection for the induction and maintenance of procedural sedation

IBT-V02: Staphylococcus aureus vaccine that confers protection in mouse and rabbit

SGN-B6A demonstrates promising activity in solid tumor models

Discovery and preclinical evaluation of potent FLT3/AXL dual inhibitor, JR-F104

Neuren begins first-in-human study of oral NNZ-2591 in healthy volunteers

First-in-human study evaluates metarrestin in metastatic solid tumors

COVAX-19 begins phase I study in Australia

Modest activity seen with tislelizumab in phase II lymphoma study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...